IGM Biosciences, Inc. (IGMS) has an overall financial health rating of C- with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2025-08-13.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-08-12 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-08-11 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-08-08 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-08-07 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-08-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-08-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-08-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-08-01 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-31 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-30 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-07-29 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
